Phase 2 Brain Cancer Trial, Recruiting NCT02479698 Sponsor: M.D. Anderson Cancer Center Condition: Brain Cancer
Back to Brain Cancer

Phase 2 Brain Cancer Trial, Recruiting

NCT02479698
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 2 years old or older (both English and non-English speakers are welcome).
  • You have a weakened immune system, and/or you have a brain infection caused by JC virus (called PML), and/or you have any type of cancer, and/or you have HIV/AIDS, and/or you have had a solid organ transplant (such as a kidney or liver), and/or you have a specific type of skin cancer called Merkel cell tumor that can be measured on a scan.
  • You have blood in your urine (found under a microscope), or a confirmed kidney infection caused by BK virus, or a brain or organ infection caused by JC virus or polyomavirus, shown by a urine or blood test.
  • Your doctors are able to reduce your steroid medication (such as prednisone) to a low enough dose during the study.
  • You are currently taking antiviral medications (such as cidofovir or leflunomide) that are not working for you.
  • You (or your parent or guardian) are able to give written consent to participate; patients with cognitive (thinking or memory) difficulties are also eligible.
  • If you are a woman who could become pregnant, you have a negative pregnancy test and are willing to use effective birth control during the study.
  • You may be taking part in other research studies at the same time, at the lead doctor's discretion.
  • If your infection comes back after treatment, you may be able to join the trial again if you still meet all the requirements at that time.

Who may not be able to join:

  • You are currently taking a high dose of prednisone (above 0.5 mg/kg per day), or you have received certain immune-suppressing treatments — specifically ATG within the last 14 days, or donor lymphocyte infusion or Campath within the last 28 days.
  • You have another active infection that is not under control (HIV/AIDS is an exception) — for example, a bacterial infection that has not been stable for at least 3 days, or a fungal infection that has not been stable for at least 1 week, on appropriate treatment.
  • You are currently experiencing a significant reaction where donated cells are attacking your body, known as acute graft-versus-host disease (GVHD) at a moderate to severe level (grades II–IV) (confirm with trial site if unsure).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: George Chen, MD, M.D. Anderson Cancer Center

Phone: 713-792-3630

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
23 July 2015
Est. completion
31 July 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Response, defined as response (R) = (best response [R1] or second best response [R2]); Incidence of acute graft-versus-host disease (GVHD); Incidence of adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov